Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on ARCT stock, giving a Buy rating on October 1.

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT ...

Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of ...

Providing a diverse range of perspectives from bullish to bearish, 3 analysts have published ratings on Arcturus Therapeutics (NASDAQ:ARCT) in the last three months. The table below summarizes ...

A total solar eclipse in April. Beautiful northern lights in May. Now, October is giving Ohioans a chance to see possibly the ...

On Wednesday, H.C. Wainwright maintained a positive outlook on Arcturus Therapeutics (NASDAQ:ARCT), reiterating a Buy rating and a $63.00 price target for the stock. The firm's stance comes after ...

On Wednesday, H.C. Wainwright maintained a positive outlook on Arcturus Therapeutics (NASDAQ:ARCT), reiterating a Buy rating and a $63.00 price target for the stock. The firm's stance comes after ...

Corona Borealis, "The Northern Crown,” is one of those rare constellations that actually looks like what it represents. It is ...

Discover Arcturus Therapeutics' groundbreaking patent for mRNA constructs targeting cystic fibrosis. Learn how innovative lipid formulations may transform treatment options.

Arcturus Therapeutics (NASDAQ:ARCT), a biotechnology company specializing in infectious disease vaccines and rare disease treatments, is navigating a complex landscape of technological innovation ...